202 related articles for article (PubMed ID: 33435509)
1. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.
Schwabl P; Hambruch E; Budas GR; Supper P; Burnet M; Liles JT; Birkel M; Brusilovskaya K; Königshofer P; Peck-Radosavljevic M; Watkins WJ; Trauner M; Breckenridge DG; Kremoser C; Reiberger T
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33435509
[TBL] [Abstract][Full Text] [Related]
2. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
4. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
[TBL] [Abstract][Full Text] [Related]
5. Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.
Hollenback D; Hambruch E; Fink G; Birkel M; Schulz A; Hornberger M; Liu K; Staiger KM; Krol HD; Deuschle U; Steeneck C; Kinzel O; Liles JT; Budas G; Watkins WJ; Kremoser C
J Pharmacol Exp Ther; 2024 Feb; ():. PubMed ID: 38409114
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
[TBL] [Abstract][Full Text] [Related]
7. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
8. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
10. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
Meng Q; Duan XP; Wang CY; Liu ZH; Sun PY; Huo XK; Sun HJ; Peng JY; Liu KX
Acta Pharmacol Sin; 2017 Jan; 38(1):69-79. PubMed ID: 27773935
[TBL] [Abstract][Full Text] [Related]
11. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
[No Abstract] [Full Text] [Related]
12. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Yang YY; Liu RS; Lee PC; Yeh YC; Huang YT; Lee WP; Lee KC; Hsieh YC; Lee FY; Tan TW; Lin HC
Liver Int; 2014 Apr; 34(4):521-34. PubMed ID: 23998651
[TBL] [Abstract][Full Text] [Related]
13. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model.
Francque S; Wamutu S; Chatterjee S; Van Marck E; Herman A; Ramon A; Jung A; Vermeulen W; De Winter B; Pelckmans P; Michielsen P
Liver Int; 2010 Mar; 30(3):365-75. PubMed ID: 19840249
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
Younis IR; Kirby BJ; Billin AN; Xiao D; Song Q; Watkins TR; Othman AA
Clin Transl Sci; 2023 Mar; 16(3):536-547. PubMed ID: 36573450
[TBL] [Abstract][Full Text] [Related]
16. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
[TBL] [Abstract][Full Text] [Related]
18. Haemodynamic effects of combined treatment with molsidomine and propranolol on portal hypertension in conscious and unrestrained cirrhotic rats.
Hori N; Okanoue T; Sawa Y; Mori T; Kashima K
J Gastroenterol Hepatol; 1996 Oct; 11(10):985-92. PubMed ID: 8912139
[TBL] [Abstract][Full Text] [Related]
19. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
Yang YY; Huang YT; Tsai TH; Hou MC; Lee FY; Lee SD; Lin HC
Clin Sci (Lond); 2012 Dec; 123(12):669-80. PubMed ID: 22734967
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
